48,830
edits
Difference between revisions of "CDX2"
Jump to navigation
Jump to search
no edit summary
| Line 1: | Line 1: | ||
{{ Infobox immunostain | |||
| Name = {{PAGENAME}} | |||
| Image = Thyroid PapillaryCarcinoma CribriformMorularVariant CDX2 HP 13BR***.jpg | |||
| Width = | |||
| Caption = CDX2 immunostaining in the [[papillary thyroid carcinoma cribriform morular variant]]. | |||
| Abbrev = CDX2 | |||
| Synonyms = | |||
| Similar = | |||
| Clones = | |||
| Use = | |||
| Subspecial = | |||
| Pattern = nuclear | |||
| Positive = colorectal adenocarcinoma, small bowel adenocarcinoma, [[yolk sac tumour]], [[ovarian mucinous adenocarcinoma]] | |||
| Negative = [[lung adenocarcinoma]] | |||
| Other = | |||
}} | |||
'''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain. | '''CDX2''' is a commonly used [[immunostain]] in pathology. It is a nuclear stain. | ||
| Line 6: | Line 21: | ||
==Pathology== | ==Pathology== | ||
*Intestinal adenocarcinomas | ===Positive=== | ||
*Intestinal adenocarcinomas - esp. [[colorectal adenocarcinoma]]. | |||
*[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | *[[Ovarian mucinous adenocarcinoma]] +ve.<ref name=pmid14668551/> | ||
===Negative or positive=== | |||
*[[Yolk sac tumour]] (8 of 20 cases - versus glypican-3).<ref name=pmid19578052>{{Cite journal | last1 = Bing | first1 = Z. | last2 = Pasha | first2 = T. | last3 = Tomaszewski | first3 = JE. | last4 = Zhang | first4 = P. | title = CDX2 expression in yolk sac component of testicular germ cell tumors. | journal = Int J Surg Pathol | volume = 17 | issue = 5 | pages = 373-7 | month = Oct | year = 2009 | doi = 10.1177/1066896909338598 | PMID = 19578052 }}</ref> | |||
*[[Small bowel]] adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases<ref name=pmid24603585>{{Cite journal | last1 = Jun | first1 = SY. | last2 = Eom | first2 = DW. | last3 = Park | first3 = H. | last4 = Bae | first4 = YK. | last5 = Jang | first5 = KT. | last6 = Yu | first6 = E. | last7 = Hong | first7 = SM. | title = Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. | journal = Mod Pathol | volume = | issue = | pages = | month = Mar | year = 2014 | doi = 10.1038/modpathol.2014.36 | PMID = 24603585 }}</ref>). | |||
===Negative=== | |||
*[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal | last1 = Tanaka | first1 = S. | last2 = Saito | first2 = K. | last3 = Ito | first3 = T. | last4 = Tajima | first4 = K. | last5 = Mogi | first5 = A. | last6 = Shitara | first6 = Y. | last7 = Sano | first7 = T. | last8 = Kuwano | first8 = H. | title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. | journal = Oncol Rep | volume = 18 | issue = 1 | pages = 87-92 | month = Jul | year = 2007 | doi = | PMID = 17549351 }}</ref>). | *[[Lung adenocarcinoma]] -ve (<5% +ve in 20 cases<ref name=pmid17549351>{{Cite journal | last1 = Tanaka | first1 = S. | last2 = Saito | first2 = K. | last3 = Ito | first3 = T. | last4 = Tajima | first4 = K. | last5 = Mogi | first5 = A. | last6 = Shitara | first6 = Y. | last7 = Sano | first7 = T. | last8 = Kuwano | first8 = H. | title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. | journal = Oncol Rep | volume = 18 | issue = 1 | pages = 87-92 | month = Jul | year = 2007 | doi = | PMID = 17549351 }}</ref>). | ||
==References== | ==References== | ||